Navigation Links
Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation
Date:11/8/2010

BEDMINSTER, N.J., Nov. 8, 2010 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova™, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza®, the leading prescription Omega-3.  Epanova is an Omega-3 fatty acid compound containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The primary objective of the four-week study, called ECLIPSE (Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation), is to compare the bioavailability of EPA from Epanova and Lovaza in either a low or high fat diet setting.  

The study will include 50 subjects.  In the four cross-over periods, all subjects will be given a single 4-gram dose of either Epanova or Lovaza with low and high fat meals.  Data is expected from this study in the first quarter of 2011.

"Several studies have compared the absorption of Omega-3 fatty acids in the ethyl ester and free fatty acid forms and found that the free fatty acid form has up to four times greater bioavailability. Given that Epanova is a free fatty acid form of EPA and DHA, whereas Lovaza is an ethyl ester EPA and DHA product, Epanova may offer distinct advantages in the marketplace," said Dr. Michael Davidson, Chief Medical Officer of Omthera Pharmaceuticals.  "Further, free fatty acid Omega-3s are well absorbed when given with a low fat meal and may therefore have clinical relevance in patients with hypertriglyceridemia who should be maintained on a low fat diet."

About Epanova™Epanova is a patent protected, novel, ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  Omthera has deve
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. Releases Selected Projected Financial Information
2. Biostar Pharmaceuticals, Inc. Expands Rural Network by Over 21% in Third Quarter 2010; Brings Total Number of Locations to 8,500
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
7. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
8. NanoSmartâ„¢ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
10. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
11. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
(Date:12/15/2014)... NEW YORK , Dec. 15, 2014  GlassesOff ... Yuval Bar-Gil as an independent director of ... was founder of AeroScout and served as its CEO ... Decker in 2012, a $240 million transaction. Recognized as ... under Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID ...
(Date:12/13/2014)... , Dec. 12, 2014 /CNW/ - MaRS and Virgin ... today that they have joined forces to support Canadian entrepreneurs ... , Virgin Group Founder was at the MaRS Centre to ... new, national impact venture fund. This fund has $1 million ... Vancouver -based Mindset Social Innovation Foundation, founded ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... Barr Pharmaceuticals,Inc. (NYSE: BRL ) today announced ... Jersey has ruled in favor of its subsidiary, Barr,Laboratories, ... Bayer Schering,Pharma, AG in connection with Bayer Schering,s Yasmin(R) ... Peter G.,Sheridan found that the patent at issue was ...
... Iomai Corporation,(Nasdaq: IOMI ) today announced that ... before the markets open and hold a,conference call and ... March 6, 2008 at 1:30 p.m. Eastern Time., ... call on Thursday, March 6 at 1:30 p.m.,Eastern Time ...
... in a row,the capital markets succumbed to fears of inflation ... the Dow dropped over 300 points after,oil prices pushed past ... was dragged down with the Burrill Biotech Select Index,dropping 4% ... closed down,3%., "The biotech sector started 2008 on a ...
Cached Biology Technology:Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge 2Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge 3Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge 4Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6 2Biotech Drops Amid Tough Markets in February 2Biotech Drops Amid Tough Markets in February 3
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Spring Harbor, N.Y. Much like cancer cells, plant ... normal milieu, in culture dishes, have highly unstable genomes. ... help cells cope with challenging culture conditions but inadvertently ... bits of DNA that can jump around in the ...
... change will reach a tipping point in less than ... of the planet,s coral reef ecosystems according to the ... by the Global Coral Reef Monitoring Network and the ... "Status of Coral Reefs of the World: 2008" provides ...
... State University chemist could eventually lead to a quicker ... key to treating a number of diseases, including cancer, ... and research often are made within genetically modified ... to collect into what scientists call inclusion bodies. Those ...
Cached Biology News:CSHL researchers map changing epigenetic modifications that enable transposons to run amok 2Time running out on coral reefs as climate change becomes increasing threat 2Time running out on coral reefs as climate change becomes increasing threat 3
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Proline-serine-threonine phosphatase-interacting protein 2...
Anti-gamma Glutamyl Transferase (gammaGT) Host: mouse monoclonal Species Reactivity: human Applications: WB, IP, FC Storage: 4C...
... Goat polyclonal to Cholesterol Oxidase ... / Specificity Cross-reacts with bacteria. Not ... Information Cholesterol oxidases exist as both ... are implicated in bacterial pathogenesis. In addition, ...
Biology Products: